DHR
Danaher Corp /De/Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP adjusted diluted net earnings per common share non-GAAP | $2.06 | Q1 2026 | — |
| Non-GAAP core revenue growth non-GAAP | 0.5% | Q1 2026 | — |
|
|
|||
| Non-GAAP free cash flow non-GAAP | $1.1B | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DHR
this stock
Danaher Corp /De/
|
$138.71B | -16.3% | +8.5% | 37.8 | 1.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$195.48B | -9.4% | +0.4% | 28.9 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.59B | -17.4% | +10.4% | 41.6 | 2.5% |
|
NTRA
Natera, Inc.
|
$39.20B | +23.0% | -2.8% | — | 4.1% |
|
A
Agilent Technologies, Inc.
|
$37.74B | -1.4% | +6.4% | 26.8 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DHR | +0.2% | +4.2% | -18.7% | +0.2% | -16.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +0.3% | +3.3% | -26.1% | +0.3% | -25.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.